` MD1 (Medistim ASA) vs DAX Index Comparison - Alpha Spread

MD1
vs
D
DAX Index

Over the past 12 months, MD1 has significantly outperformed DAX Index, delivering a return of +34% compared to the DAX Index's +9% growth.

Stocks Performance
MD1 vs DAX Index

Loading
MD1
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MD1 vs DAX Index

Loading
MD1
DAX Index
Difference
www.alphaspread.com

Performance By Year
MD1 vs DAX Index

Loading
MD1
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Medistim ASA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Medistim ASA
Glance View

Medistim ASA engages in the development, manufacturing, and distribution of medical equipment and consumables. The company is headquartered in Oslo, Oslo. The company went IPO on 2004-05-28. The company develops, manufactures and distributes medical devices primarily for cardiac and vascular surgery. The firm provides intra-operative standard control applications designed to verify and document quality during surgery. Its product portfolio comprises systems, such as ultrasound imaging systems VeriQ C and MiraQ, as well as probes, which offer Transit Time Flow Measurement (TTFM). The Company’s activities are divided into four business areas: lease of equipment within cardiac surgery, capital and consumable sales within cardiac surgery, sales of electronic stethoscopes and distribution and sales of third party products. Furthermore, the Company is a parent of Medistim USA Inc, Medistim Deutschland GmbH, and Medistim Norge AS, among others.

MD1 Intrinsic Value
16.42 EUR
Overvaluation 8%
Intrinsic Value
Price
Back to Top